Latest news with #NASDAQGlobalMarket
Yahoo
21-05-2025
- Business
- Yahoo
ESSA Bancorp, Inc. Declares Quarterly Dividend
STROUDSBURG, PA / / May 21, 2025 / ESSA Bancorp, Inc. (NASDAQ Global MarketSM:ESSA), the holding company for ESSA Bank & Trust, today announced that its Board of Directors declared a dividend of fifteen cents ($0.15) per share. The dividend is payable to shareholders of record as of June 16, 2025, payable on June 30, 2025. About the Company ESSA Bancorp, Inc. is the holding company for its wholly owned subsidiary, ESSA Bank & Trust, which was formed in 1916. The Company has total assets of $2.2 billion. Headquartered in Stroudsburg, Pennsylvania, the Company has two regional offices in Allentown and Radnor, and operates 19 community offices throughout the greater Pocono, Lehigh Valley, Scranton/Wilkes-Barre, and suburban Philadelphia areas. ESSA Bank & Trust offers a full range of commercial and retail financial services, asset management and trust services, investment services through Ameriprise Financial Institutions Group and insurance benefit services through ESSA Advisory Services, LLC. ESSA Bancorp Inc. stock trades on the NASDAQ Global Market (SM) under the symbol "ESSA". Forward-Looking Statements Certain statements contained herein are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements may be identified by reference to a future period or periods, or by the use of forward-looking terminology, such as "may," "will," "believe," "expect," "estimate," "anticipate," "continue," or similar terms or variations on those terms, or the negative of those terms. Forward-looking statements are subject to numerous risks and uncertainties, including, but not limited to, those related to the economic environment, particularly in the market areas in which the Company operates, competitive products and pricing, fiscal and monetary policies of the U.S. Government, changes in government regulations affecting financial institutions, including compliance costs and capital requirements, changes in prevailing interest rates, acquisitions and the integration of acquired businesses, credit risk management, asset-liability management, the financial and securities markets and the availability of and costs associated with sources of liquidity, and the risk factors disclosed in the Company's most recent Annual Report on Form 10-K and subsequent Quarterly Reports filed on Form 10-Q. The Company wishes to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company wishes to advise readers that the factors listed above could affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed with respect to future periods in any current statements. The Company does not undertake and specifically declines any obligation to publicly release the result of any revisions, that may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events. Contact: Gary S. Olson, President & CEOCorporate Office: 200 Palmer StreetStroudsburg, Pennsylvania 18360Telephone: (855) 713-8001 SOURCE: ESSA Bancorp Inc. View the original press release on ACCESS Newswire
Associated Press
27-03-2025
- Business
- Associated Press
Loop Industries to Participate in Gabelli Funds' 11th Annual Waste & Sustainability Symposium
MONTREAL, QC / ACCESS Newswire / March 27, 2025 / Loop Industries, Inc. (NASDAQ:LOOP) ('Loop'), a clean technology company dedicated to acceleratinga circular plastics economy and circular fashion by manufacturing 100% recycled polyethylene terephthalate (PET) plastic and textile-to-textile polyester fiber, today announced that Daniel Solomita, Founder and CEO, and Kevin O'Dowd, Head of Investor Relations, will be participating in Gabelli Funds' 11th Annual Waste & Sustainability Symposium. Event Details: Location: The Harvard Club, New York City, NY Time: Loop Industries will present at 2:15 PM During the conference, Loop will hold a group presentation and engage in one-on-one meetings with institutional investors and financial analysts. For Virtual Participation: Interested parties are encouraged to register for a virtual meeting through the Gabelli Funds conference portal. Registration Link: Gabelli Conference Registration About Loop Industries Loop Industries is a technology company whose mission is to accelerate the world's shift toward sustainable PET plastic and polyester fiber and away from our dependence on fossil fuels. Loop Industries owns patented and proprietary technology that depolymerizes no and low-value waste PET plastic and polyester fiber, including plastic bottles and packaging, carpets and textiles of any color, transparency or condition and even ocean plastics that have been degraded by the sun and salt, to its base building blocks (monomers). The monomers are filtered, purified and polymerized to create virgin-quality Loop™ branded PET resin suitable for use in food-grade packaging and polyester fiber, thus enabling our customers to meet their sustainability objectives. Loop™ PET plastic and polyester fiber can be recycled infinitely without degradation of quality, successfully closing the plastic loop. Loop Industries is contributing to the global movement towards a circular economy by reducing plastic waste and recovering waste plastic for a sustainable future. Common shares of the Company are listed on the NASDAQ Global Market under the symbol 'LOOP.'
Associated Press
25-03-2025
- Business
- Associated Press
NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors
WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (to be listed on the NASDAQ Global Market under the symbol: NTHI), a clinical-stage medical biotechnology company, today announced the appointment of Dr. Steven L. Giannotta, a distinguished neurosurgeon and former Chair of Neurological Surgery at the University of Southern California (USC), to its Board of Directors. Dr. Giannotta brings over four decades of expertise in cerebrovascular and cranial base surgery, with contributions to cerebral blood flow research, ischemia prevention, and innovative surgical techniques. 'Steven's extensive background in neurological surgery, especially his leadership in advancing both research and surgical techniques for cerebrovascular diseases, will be invaluable to our Company,' said Dr. Thomas Chen, CEO of NeOnc. 'We look forward to having his expertise and visionary perspective shape our progress as we continue to advance our mission of pursuing innovative solutions that enhance patient care, bring hope, and extend lives.' Dr. Giannotta joined the USC Department of Neurosurgery in 1980, and has since become internationally recognized for his groundbreaking work in cerebrovascular disease, including pioneering 'hyperdynamic therapy' as a clinical approach to combat cerebral vasospasm. His research interests encompass cerebral blood flow, ischemia, and the impact of ethnic differences on cerebrovascular disorders. Dr. Giannotta's clinical achievements include performing over 1,000 intracranial aneurysm surgeries and developing a comprehensive, multidisciplinary approach to complex cerebrovascular conditions. 'I am thrilled to be a part of NeOnc's Board of Directors,' said Dr. Giannotta. 'I have spent my entire professional career on development of dynamic therapies, and believe NeOnc is on the right path with the same mission.' 'Dr. Giannotta's dedication to improving patient outcomes and pioneering innovative approaches aligns seamlessly with our core values,' said Amir Heshmatpour, Executive Chairman of NeOnc. 'We believe his wealth of experience in managing complex cerebrovascular conditions will greatly enhance our ability to deliver cutting-edge solutions in neurosurgical care.' Dr. Giannotta earned his medical degree, and completed his residency, at the University of Michigan. He remains deeply engaged with several national and international neurosurgical committees, furthering both clinical advancements and educational initiatives in his field. ABOUT NEONC TECHNOLOGIES HOLDINGS, INC. NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company's NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc's NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions. For more about NeOnc and its pioneering technology, visit Important Cautions Regarding Forward Looking Statements All statements other than statements of historical facts included in this press release are 'forward-looking statements' (as defined in the Private Securities Litigation Reform Act of 1995). Generally, such forward-looking statements include statements regarding expectations, possible or assumed future actions, business strategies, events or results of operations, including statements regarding our expectations or predictions or future financial or business performance or conditions and those statements that use forward-looking words such as 'projected,' 'expect,' 'possibility' and 'anticipate,' or similar expressions. The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions. Actual results could differ materially from current projections or implied results. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management are under no obligation, and expressly disclaim any obligation, to update, alter or otherwise revise any forward-looking statements following the date of this news release, whether because of new information, future events or otherwise, except as required by law. 'NEO100' is a registered trademark of NeOnc Technologies Holdings, Inc. Company Contact: Patrick Walters Chief Operations Officer NeOnc Technologies Holdings, Inc. Investor Relations: Roger Pondel / Laurie Berman PondelWilkinson Inc. (310) 279-5980
Yahoo
19-03-2025
- Business
- Yahoo
Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results
Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) ('Inventiva' or the 'Company'), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ('MASH') and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company's 2024 full-year financial results on Thursday, March 27, 2025. Inventiva's 2024 full-year financial results will be published on Wednesday, March 26, 2025 at 4:00 pm (New York), 9:00 pm (Paris). Frédéric Cren, CEO and cofounder of Inventiva and Jean Volatier, Chief Financial Officer of Inventiva will hold a conference call in English, followed by a Q&A session, on Thursday, March 27, 2025, at 8:00 am (New York), 1:00 pm (Paris). The conference call and the slides of the presentation will be webcast live here. In order to receive the conference access information necessary to join the conference call, it is required to register in advance here. Participants will need to use the conference access information provided in the e-mail received at the point of registering (dial-in number and access code). A replay of the conference call and the presentation will be available after the event on our website. About Inventiva Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. The Company has a scientific team of approximately 90 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly owned research and development facility. Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the NASDAQ Global Market in the United States (ticker: IVA). Contacts Inventiva Pascaline ClercEVP, Strategy and Corporate Affairsmedia@ +1 202 499 8937 Brunswick GroupTristan Roquet MontegonAude Lepreux Julia CailleteauMedia relationsinventiva@ +33 1 53 96 83 83 ICR HealthcarePatricia L. BankInvestor relations +1 415 513 1284 Attachment Inventiva - PR - Webcast invitation FY 2024 - EN - 03 19 2025-Sign in to access your portfolio
Associated Press
04-02-2025
- Business
- Associated Press
Horizon Space Acquisition II Corp. Announces the Separate Trading of its Ordinary Shares and Rights, Commencing on February 5, 2025
NEW YORK CITY, NY / ACCESS Newswire / February 4, 2025 / Horizon Space Acquisition II Corp. (the 'Company') (Nasdaq:HSPT), a blank check company, today announced that, commencing on February 5, 2025, holders of the 5,750,000 units (the 'Units') sold in the Company's initial public offering (the 'Offering') including Units sold upon a full exercise of the underwriters' over-allotment option, may elect to separately trade the ordinary shares and rights included in the Units. Any Units not separated will continue to trade on the NASDAQ Global Market ('NASDAQ') under the symbol 'HSPTU.' Any underlying ordinary shares and rights that are separated will trade on the NASDAQ under the symbols 'HSPT' and 'HSPTR,' respectively. Holders of Units will need to have their brokers contact the Company's transfer agent, VStock Transfer, LLC, in order to separate the holders' Units into ordinary shares and rights. The Units were initially offered by the Company in an underwritten offering. Maxim Group LLC acted as the representative of the underwriters for the Offering. A registration statement on Form S-1 (File No. 333-282758) relating to these securities was declared effective by the Securities and Exchange Commission (the 'SEC') on November 12, 2024. The Offering was made only by means of a prospectus, copies of which may be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, or by visiting EDGAR on the SEC's website at This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Horizon Space Acquisition II Corp. Horizon Space Acquisition II Corp. is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. Horizon Space Acquisition II Corp. intends to focus on prospective target business that is not limited to a particular industry or geographic region. Because of the Company's significant ties to China, it may pursue opportunities in China (including Hong Kong and Macau). Forward-Looking Statements This press release contains statements that constitute 'forward-looking statements,' including with respect to the expected closing of the Company's initial public offering and search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or at all. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related preliminary prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC's website, The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. Mingyu (Michael) Li
